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OBJECTIVES The aim of this study was to evaluate tecadenoson safety and efficacy during conversion of
paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.
BACKGROUND Tecadenoson (CVT-510), a novel adenosine receptor (Ado R) agonist, selectively activates
the A1 Ado R and prolongs atrioventricular (AV) nodal conduction at doses lower than those
required to cause A2 Ado R-mediated coronary and peripheral vasodilation. Unlike
adenosine, which non-selectively activates all four Ado R subtypes and produces unwanted
effects, tecadenoson appears to terminate AV node-dependent supraventricular tachycardias
without hypotension and bronchoconstriction.
METHODS In this open-label, multicenter, dose escalation study, tecadenoson was administered to 37
patients (AV node re-entrant tachycardia, n  29; AV re-entrant tachycardia, n  8) with
inducible PSVT sustained for1 min during an electrophysiology study. Seven regimens (0.3
to 15 g/kg) of up to two identical tecadenoson intravenous bolus doses were administered.
RESULTS After the first or second bolus, PSVT converted to sustained sinus rhythm for 5 min in
86.5% (32/37) of the patients, with 91% (29/32) of the conversions occurring after the first
bolus (most within 30 s), coincident with anterograde conduction block in the AV node. No
effects on sinus cycle length (SCL) or systolic blood pressure were observed. The atrial-His
(AH), but not the His-ventricular (HV) interval was prolonged up to 5 min after the final
tecadenoson bolus, returning to baseline by 10 min. Tecadenoson was generally well tolerated.
CONCLUSIONS In this study, tecadenoson rapidly terminated sustained PSVT by depressing AV nodal
conduction without causing hypotension. After sinus rhythm restoration, there was minimal
AH interval prolongation without HV interval or SCL prolongation. (J Am Coll Cardiol
2003;42:1098–102) © 2003 by the American College of Cardiology Foundation
The cardiac actions of adenosine include slowing of sinus
rate, depression of atrioventricular (AV) nodal conduction,
depression of atrial, but not ventricular contractility, short-
ening of atrial but lengthening of the AV nodal refractory
period, and attenuation of the stimulatory effects of cat-
echolamines on the myocardium (1,2). These actions of
adenosine are mediated by the A1 adenosine receptor (Ado
R) subtype and are, for the most part, due to the direct
activation of the inward rectifying potassium current and
inhibition of catecholamine-stimulated ion currents such as
the pacemaker current and the L type calcium currents
(2,3).
The Ado R-mediated negative dromotropic effect of
adenosine is the basis for the use of this nucleoside to
interrupt transiently AV nodal conduction during paroxys-
mal supraventricular tachycardia (PSVT) (4,5). This results
in conversion of PSVT to sinus rhythm in a majority of
cases of AV node-dependent tachycardia such as AV nodal
re-entry and AV re-entry (6). Although adenosine is effec-
tive in terminating PSVT, significant limitations to its use
include a high incidence of subjective symptoms and ar-
rhythmias at the time of conversion (55%) (7). Shortening
of the atrial action potential and refractory period may
promote the development of atrial flutter or fibrillation
(5,6,8).
Tecadenoson (6-[N-3-(R)-tetrahydrofuranyl]-amino-
purine riboside or CVT-510) is a novel selective A1 Ado R
agonist. The functional selectivity of tecadenoson for an A1
Ado R has been demonstrated in an anesthetized, atrial-
paced guinea pig heart model (9). In these studies, intrave-
nous (IV) tecadenoson prolonged the PR interval without
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reducing systemic blood pressure (9). Additionally, in
guinea pig isolated hearts, tecadenoson was approximately
five-fold more potent in prolonging the stimulus-to-His
bundle (S-H) interval, an A1 Ado R effect, than in increas-
ing coronary conductance, an A2A Ado R-mediated effect
(9). In the same model, tecadenoson was three-fold more
potent in prolonging the S-H interval than in shortening
the atrial action potential. In contrast, adenosine has a
greater effect on the A2A rather than the A1 Ado
R-mediated effects, and is equipotent in prolonging the
S-H interval and in shortening the atrial action potential
(10,11). Thus, a selective A1 Ado R agonist such as
tecadenoson may offer an advantage over adenosine for
conversion of PSVT to sinus rhythm, while minimizing the
incidence of atrial proarrhythmias, hypotension, or bron-
choconstriction.
In a previous study, the electrophysiologic effects of
tecadenoson were determined in 32 patients with normal
AV nodal function (12). Tecadenoson administered in IV
bolus doses of 0.3 to 10 g/kg caused rapid and transient
dose-dependent increases in the atrial-His (AH) interval
without affecting blood pressure, sinus cycle length (SCL),
or His-ventricular (HV) interval (12). At doses of 15 and 30
g/kg, transient second- and third-degree AV block in
sinus rhythm was observed (12). The purpose of the present
study was to determine the safety and efficacy of bolus doses
of tecadenoson to convert PSVT induced during electro-
physiology study to sinus rhythm in patients with a history
of tachycardia.
METHODS
Study design. This was a multicenter, dose-escalation
study in which patients with a history of spontaneous PSVT
were dosed with tecadenoson in an open-label fashion
during the course of a routinely scheduled clinical electro-
physiology study. The protocol and informed consent forms
for this study were approved by the institutional review
committees at all the respective study centers. All patients
gave written informed consent before enrollment. All anti-
arrhythmic medications were withheld for five half-lives
before the electrophysiology study. Standard electrophysi-
ologic techniques were employed (6). In brief, three to four
multipolar electrode catheters were inserted intravenously
and positioned in the right atrium, right ventricle, His
bundle area, and coronary sinus. Programmed atrial and
ventricular stimulations were performed, PSVT was in-
duced, and the diagnosis of atrioventricular node re-entrant
tachycardia (AVNRT) or atrioventricular re-entrant tachy-
cardia (AVRT) was made using standard criteria. Tecade-
noson was administered via a peripheral vein after PSVT
had been sustained for at least 1 min. After the first bolus,
if PSVT had not converted to sustained sinus rhythm, a
second identical bolus of tecadenoson was administered.
The shortest time between consecutive doses of tecadenoson
was 2 min. The effects of the following dose regimens were
studied in 37 patients: up to two identical bolus doses of 0.3
g/kg (n 1); 3 g/kg (n 4); 5 g/kg (n 9); 7.5 g/kg
(n  4); 10 g/kg (n  5); 12.5 g/kg (n  4); and 15
g/kg (n  10).
Cycle length, blood pressure, AH and HV intervals, atrial
effective refractory period, ventricular effective refractory
period, sinus node recovery time (SNRT) were determined,
and a 12-lead electrocardiogram was recorded at defined
time points throughout the study (baseline and after admin-
istration of tecadenoson). In instances where isoproterenol
was needed for initiation of PSVT, electrophysiologic mea-
surements before and after tecadenoson administration were
obtained without a change in isoproterenol dose. Blood
samples for determination of plasma levels of tecadenoson
were also obtained.
Statistical methods. The rate of conversion of PSVT to
sustained sinus rhythm was calculated for all patients and is
expressed as a percentage of the total number of patients
dosed. All other results (blood pressure, cycle length, intra-
cardiac intervals and refractory periods, as well as SNRT)
are expressed as mean  SEM. Two sample t tests were
performed to compare patients who did and did not receive
isoproterenol. Paired t tests were performed to compare
baseline with post-dose values. Fisher exact tests were
performed to compare rates of conversion. A value p 0.05
was considered to be statistically significant.
RESULTS
Patient characteristics. All 37 patients, 14 male, had a
history of symptomatic PSVT that was due to AVNRT in
29 (78%) patients and AVRT in 8 (22%) patients. The
mean age was 45 years (range 19 to 81 years). The PSVT
episodes were more than 10 per year in 14 (38%) patients,
and overall 19 of 37 patients had previously received
adenosine, 16 of whom responded to it. The mean cycle
length of sustained PSVT was 323 ms (range 240 to 460
ms) for all patients and was not different between patients
with AVNRT (328  10 ms) and AVRT (306  12 ms).
The PSVT cycle length was significantly shorter in the 19
patients who received isoproterenol (298  8 ms) compared
Abbreviations and Acronyms
Ado R  adenosine receptor
AH  atrial-His
AV  atrioventricular
AVNRT  atrioventricular node re-entrant tachycardia
AVRT  atrioventricular re-entrant tachycardia
Cmax  maximum plasma level
HV  His-ventricular
IV  intravenous
PSVT  paroxysmal supraventricular tachycardia
SCL  sinus cycle length
S-H  stimulus-to-His bundle interval
SNRT  sinus node recovery time
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with 18 patients who did not receive isoproterenol (349 
12 ms; p  0.0013) for induction of PSVT.
Effect of tecadenoson on PSVT conversion. Paroxysmal
supraventricular tachycardia of at least 1 min duration was
converted to sustained (5 min) sinus rhythm in 32 of 37
patients (86.5%) after administration of one or two boluses
of tecadenoson. Conversion to sinus rhythm occurred after
the first bolus of tecadenoson in 29 of 32 patients (91%),
and 66% of these conversions (19 of 29 patients) occurred
within 30 s after administration of the bolus. There were 26
of 29 (90%) patients with AVNRT who converted with
tecadenoson. In the 24 patients in whom the site of block
was documented, 23 converted with anterograde block in
the slow pathway and 1 with anterograde block in the fast
pathway. Tecadenoson caused termination of PSVT in 6 of
8 (75%) patients with AVRT. The PSVT termination site
was documented in five patients, and the AV node was the
site of block in all patients. One patient had transient
termination with anterograde block in the AV node, but
PSVT resumed within a few seconds. The number of
patients tested at each dose level was too small to detect any
dose-related trends in the conversion rate of PSVT to sinus
rhythm (Fig. 1). The success rate of conversion to sinus
rhythm was lower in patients requiring isoproterenol to
sustain their PSVT (15 of 19 patients; 79%) than in the
cohort of patients who did not require isoproterenol to
sustain their PSVT (17 of 18 patients; 94%); however, this
difference was not significant (p  0.34). The single patient
dosed at 0.3 g/kg failed to convert to sinus rhythm;
however, tachycardia transiently slowed after each bolus in
this patient.
Effect of tecadenoson on SCL, blood pressure, AH and
HV intervals. There were no significant effects of tecade-
noson on the SCL or systolic blood pressure after conver-
sion of PSVT to sinus rhythm (Table 1). There was a
minimal increase in mean diastolic blood pressure from 69
to 74 mm Hg 1 min after dosing (p  0.01). The AH
interval, but not the HV interval, was transiently and
significantly prolonged (p  0.005) at the 1- and 5-min
time points after the final dose of tecadenoson, returning to
baseline by 10 min post-dose.
Pharmacokinetics and pharmacodynamics of tecadeno-
son. The pharmacokinetic profile of tecadenoson deter-
mined using a two-compartment model showed that peak
plasma levels were achieved immediately (30 s) after IV
bolus administration, with a rapid decline within 2 min due
to distribution. The terminal elimination half-life was
approximately 30 min. The second bolus produced a peak
plasma level that was only marginally higher than that
observed after the first bolus owing to the rapid distribution
of tecadenoson after IV bolus injection. The overall phar-
macokinetic results did not indicate any deviation from dose
proportionality. The peak plasma levels were independent of
body weight or gender, implying that uniform (non–weight-
based) dosing could be used to minimize variability between
patients receiving the same dose. The conversion of PSVT
occurred approximately at the maximum plasma level (Cmax)
in all instances. This is consistent with the observation that
the mean time to conversion was within 30 s after comple-
tion of the bolus.
Adverse events. Nine patients (24%) had 15 adverse events
on the day of tecadenoson administration (Table 2). Eight
Figure 1. Summary of the conversion of paroxysmal supraventricular
tachycardia to sinus rhythm by tecadenoson. Conversion rates (in percent-
ages) after the first (stippled bars) and second (unfilled bars) boluses of
tecadenoson are shown. The dose of tecadenoson (g/kg) administered is
indicated below each bar, and the numbers under the doses denote the
number of patients treated at each dose level. Data from one patient dosed
at 3 g/kg who did not convert to sinus rhythm is not represented here.
Table 1. Hemodynamic and Electrophysiologic Effects of Tecadenoson in Patients Who Converted After Study Drug Administration
Baseline
1 Min
After Bolus
5 Min
After Bolus
10 Min
After Bolus
20 Min
After Bolus
Systolic blood pressure (mm Hg) 128.5  3.9 136.2  4.9 130.6  3.7 130.7  4.3 ND
Diastolic blood pressure (mm Hg) 68.7  2.3 73.9  2.2* 70.4  2.6 71.1  2.7 ND
SCL (ms) 718.6  27.3 715.3  40.7 731.7  31.9 684.4  26.8 ND
A-H interval (ms) 82.8  3.8 96.6  4.3* 88.3  3.6* 83.4  4.0 ND
H-V interval (ms) 40.1  2.0 42.2  2.7 42.6  2.4 42.4  2.4 ND
SNRT (ms) 959.2  43.5 ND ND ND 860.0  46.8*
AERP (ms) 209.3  7.5 ND ND 209.6  8.6 ND
VERP (ms) 218.9  4.9 ND ND 214.8  5.4 ND
*Statistically different (p  0.05).
AERP  atrial effective refractory period; A-H  atrial-His; H-V  His-ventricular; ND  not determined; SCL  sinus cycle length; SNRT  sinus node recovery time;
VERP  ventricular effective refractory period.
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more patients (22%) reported adverse events over the next
13 days. Overall, 17 of 37 patients (46%) reported at least
one adverse event during the entire 14-day follow-up period
after receiving tecadenoson. No relationship between the
frequency of adverse events and the dose of tecadenoson was
observed. Three patients (8%) had four adverse events (9 %)
reported by the investigator as being probably or possibly
drug-related. These drug-related events were as follows:
transient 2:1 infra-His AV block that occurred with a
long-short initiating sequence of recurrent tachycardia after
PSVT had terminated following tecadenoson administra-
tion in one patient dosed at 5 g/kg; pain, described as a
burning sensation in the wrists and legs after drug was
injected, in one patient dosed at 10 g/kg; and asthenia,
described as heaviness in the arms and legs, in one patient
dosed at 15 g/kg.
DISCUSSION
The key new observations from this study are demonstration
of: 1) the efficacy rate of tecadenoson, a novel selective A1
Ado R agonist, to terminate PSVT with minimal recurrence
(3%), and 2) the relatively prolonged elimination half-life of
30 min for tecadenoson, in contrast to a few seconds for the
currently available adenosine. Further, the selectivity of
tecadenoson for the A1 Ado R, at least in part, may have
accounted for the lack of hypotension or other side effects
even with the sustained effects (up to 5 min after dosing) on
prolongation of AV conduction.
Rapid IV boluses of tecadenoson were associated with the
conversion of programmed electrical stimulation-induced
PSVT to sustained sinus rhythm in a majority (86%) of
patients, with conversion occurring within 30 s (close to
Cmax) in over one-half of the patients. Conversion of PSVT
to sinus rhythm after administration of tecadenoson was not
associated with hypotension and pro-arrhythmic effects such
as the induction of atrial fibrillation. The sample size in this
study was too small to detect any dose-related differences in
the effects of the drug in converting PSVT to sinus rhythm.
Conversion of PSVT to sinus rhythm was noted across a
wide range of doses, but there was no clear dose-related
trend in the incidence of drug-related adverse events.
The longer duration of effect of tecadenoson (minutes)
relative to that of adenosine (seconds) is consistent with the
observation that the AH interval remained prolonged for at
least 5 min after dosing. The persistent negative dromo-
tropic effect of tecadenoson on AV nodal conduction after
termination of PSVT likely explains the lack of recurrent
PSVT in the majority (97%) of patients. In contrast, the
recurrence rate after successful conversion of PSVT with
adenosine is as high as 50% (13). The lack of second- or
third-degree AV block after conversion to sinus rhythm in
the presence of a prolonged AH interval may be explained
by the intrinsic rate-dependent delay in AV nodal conduc-
tion, which is reflected in the shape of the AV node function
curve (14). During incremental atrial pacing, there is a
relatively minimal increase in the AH interval until the
pacing cycle length starts to approach the Wenckebach cycle
length. When the atrial cycle length is further shortened,
the AV node function curve becomes steep and relatively
large increases in the AH interval are observed. Importantly,
the negative dromotropic effect on the human AV node of
enhanced vagal tone (14) or verapamil (E. N. Prystowsky,
unpublished observations, 1988) is modest at slower heart
rates (flat part of AV node curve) but marked at faster rates
(steep part of AV node curve). This has also been observed
with administration of adenosine and A1 Ado R agonists in
animal models and humans (15–17). In this study, the sinus
rate after termination of PSVT by tecadenoson was similar
to the baseline rate (Table 1), and therefore one would
expect only modest increases in the AH interval, but not
heart block. Indeed, upon termination of PSVT by tecade-
noson, the AH interval was modestly prolonged at 1 and 5
min when compared with baseline (Table 1). Although this
is a relatively small prolongation of the AH interval, early
recurrence of PSVT would be unlikely because AV nodal
block would be expected if sudden increases in heart rate
unrelated to acute changes in autonomic tone occurred.
A potent A1 agonist could be relatively selective for the
AV node by slowing AV conduction at doses that do not
cause sinus bradycardia and/or marked shortening of the
atrial action potential. This is due, at least in part, to the fact
that A1 Ado R reserve is greater in the AV node than either
the atria or the sinus node (18,19). Consequently, tecade-
noson would have to activate significantly fewer A1 Ado R
in the AV node than in either the atria or the sinus node to
produce its effects. Whereas the A1 Ado R-selective prop-
erties of tecadenoson have been shown in the guinea pig
Table 2. Adverse Events Reported After Treatment With
Tecadenoson
Number of
Patients
(%)
Patients with any adverse event 17 (46)
Patients with any adverse event post dose on the day
of dosing
9 (24)
Adverse event listing
Allergic reaction to concomitant medication 2 (5)
Complete AV block after radiofrequency ablation 2 (5)
Hypotension (after withdrawal of central venous
access sheaths in 1 case)
2 (5)
Asthenia (heaviness in arms and legs)* 1 (3)
2:1 AV block during recurrent tachycardia after
PSVT conversion with tecadenoson*
1 (3)
Bradycardia (after withdrawal of central venous
access sheaths)
1 (3)
Chest pain 1 (3)
Nausea 1 (3)
Pain (burning sensation in wrists and legs)* 1 (3)
Palpitations 1 (3)
Recurrent tachycardia after PSVT conversion with
tecadenoson*
1 (3)
*Events considered probably or possibly related to administration of tecadenoson by
the investigator.
AV  atrioventricular; PSVT  paroxysmal supraventricular tachycardia.
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isolated heart and whole animal models, the present study
has demonstrated for the first time in humans that the
undesirable A2 and A3 Ado R-mediated effects of adenosine
during conversion of PSVT can be avoided by an A1
receptor subtype-selective agonist. Furthermore, this study
supports the concept that a selective A1 Ado R agonist can
be used for “smooth” uneventful termination of PSVT with
restoration of sustained sinus rhythm and minimal occur-
rence of atrial fibrillation. This is in contrast to adenosine,
which often terminates PSVT with the occurrence of
high-grade, albeit, transient AV block accompanied by
unpleasant symptoms and atrial fibrillation. For example,
the reported incidence of atrial fibrillation and/or flutter
after IV bolus injection of adenosine (12 mg) varies from
1% to 12% (20–23). The most common adverse reactions
after an IV bolus of adenosine are flushing, dyspnea, and
chest discomfort. These side effects have been reported to
occur in approximately 18%, 12%, and 7%, respectively, of
the patients treated with doses of adenosine 12 mg (20).
Further studies are needed to determine whether tecadeno-
son administered by constant infusion will be useful to
control ventricular rate in atrial fibrillation.
In this study, tecadenoson rapidly terminated PSVT by
prolonging AV nodal conduction without causing hypoten-
sion. After restoration of sinus rhythm there was minimal
prolongation of AH interval without prolongation of HV
interval, or SCL. These features make tecadenoson a
potentially advantageous alternative to current therapies for
the acute management of PSVT.
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